See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
WWE Wrestlemania
Social Media
Natural Disasters
Baseball
Soccer
Donald Trump
Tariffs
US Politics
Artificial Intelligence
White House
Education
Golf
Published • loading... • Updated

Vutrisiran Shows Sustained Benefits in Cardiac Amyloidosis

Summary by Medscape
Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with cardiomyopathy, according to a follow-up analysis of data from the HELIOS-B trial. Medscape Medical News

2 Articles

All
Left
Center
Right
hcplive.comhcplive.com

SGLT2 Inhibitors Linked to Improved Outcomes in ATTR Amyloidosis With Cardiomyopathy

Justin Riley Lam, MD, discussed findings from a retrospective cohort analysis at the 2025 ACP Internal Medicine Meeting.

Read Full Article
MedscapeMedscape

Vutrisiran Shows Sustained Benefits in Cardiac Amyloidosis

Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with cardiomyopathy, according to a follow-up analysis of data from the HELIOS-B trial. Medscape Medical News

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Wednesday, April 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Medical

Medical

Maryland

Maryland

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal